Skip to Main Content

Author Details

Xun Bao
Wayne State University School of Medicine, Barbara Ann Karmanos Cancer Institute
2014
33
13
PMIDPaper TitleJournal TitlePublished Year
38081370Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesis in vitro.Biochem Pharmacol2024
36602953Correction: Novel Pyrrolo[3,2-d]Pyrimidine Compounds Target Mitochondrial and Cytosolic One-Carbon Metabolism with Broad-spectrum Antitumor Efficacy.Mol Cancer Ther2023
37604291Acquired resistance to venetoclax plus azacitidine in acute myeloid leukemia: In vitro models and mechanisms.Biochem Pharmacol2023
37200803Multitargeted 6-Substituted Thieno[2,3-<i>d</i>]pyrimidines as Folate Receptor-Selective Anticancer Agents that Inhibit Cytosolic and Mitochondrial One-Carbon Metabolism.ACS Pharmacol Transl Sci2023
37162954Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesis.Res Sq2023
34702773A Phase 0 Trial of Ceritinib in Patients with Brain Metastases and Recurrent Glioblastoma.Clin Cancer Res2022
35727144Mechanistic Modeling of Central Nervous System Pharmacokinetics and Target Engagement of HER2 Tyrosine Kinase Inhibitors to Inform Treatment of Breast Cancer Brain Metastases.Clin Cancer Res2022
35938683Development and validation of a liquid chromatography coupled with tandem mass spectrometry method for determining total and unbound pamiparib in human plasma and brain tumors.Biomed Chromatogr2022
36208684Co-targeting of HDAC, PI3K, and Bcl-2 results in metabolic and transcriptional reprogramming and decreased mitochondrial function in acute myeloid leukemia.Biochem Pharmacol2022
36128328Targeting Krebs-cycle-deficient renal cell carcinoma with Poly ADP-ribose polymerase inhibitors and low-dose alkylating chemotherapy.Oncotarget2022
36283260Evaluation and correction of injection order effects in LC-MS/MS based targeted metabolomics.J Chromatogr B Analyt Technol Biomed Life Sci2022
32799335Physiologically Based Pharmacokinetic Modeling of Central Nervous System Pharmacokinetics of CDK4/6 Inhibitors to Guide Selection of Drug and Dosing Regimen for Brain Cancer Treatment.Clin Pharmacol Ther2021
33566445Quantitative protein expression of blood-brain barrier transporters in the vasculature of brain metastases of patients with lung and breast cancer.Clin Transl Sci2021
33773393Discovery of 6-substituted thieno[2,3-d]pyrimidine analogs as dual inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase in de novo purine nucleotide biosynthesis in folate receptor expressing human tumors.Bioorg Med Chem2021
32494005Oncometabolites suppress DNA repair by disrupting local chromatin signalling.Nature2020
31664714Protein Expression and Functional Relevance of Efflux and Uptake Drug Transporters at the Blood-Brain Barrier of Human Brain and Glioblastoma.Clin Pharmacol Ther2020
30660034Determination of total and unbound ribociclib in human plasma and brain tumor tissues using liquid chromatography coupled with tandem mass spectrometry.J Pharm Biomed Anal2019
30052267Pharmacometabolomics Reveals Irinotecan Mechanism of Action in Cancer Patients.J Clin Pharmacol2019
31359185Amino acid-linked platinum(II) compounds: non-canonical nucleoside preferences and influence on glycosidic bond stabilities.J Biol Inorg Chem2019
31375752Quantitative Profiling of Oncometabolites in Frozen and Formalin-Fixed Paraffin-Embedded Tissue Specimens by Liquid Chromatography Coupled with Tandem Mass Spectrometry.Sci Rep2019
31289137Novel Pyrrolo[3,2-<i>d</i>]pyrimidine Compounds Target Mitochondrial and Cytosolic One-carbon Metabolism with Broad-spectrum Antitumor Efficacy.Mol Cancer Ther2019
31285369A Phase 0 Trial of Ribociclib in Recurrent Glioblastoma Patients Incorporating a Tumor Pharmacodynamic- and Pharmacokinetic-Guided Expansion Cohort.Clin Cancer Res2019
30726707Corrigendum to "Gold nanoparticle conjugated Rad6 inhibitor induces cell death in triple negative breast cancer cells by inducing mitochondrial dysfunction and PARP-1 hyperactivation: Synthesis and characterization" [Nanomedicine 12 (3) (2016), 745-757].Nanomedicine2019
29568664A liquid chromatography with tandem mass spectrometry method for quantitating total and unbound ceritinib in patient plasma and brain tumor.J Pharm Anal2018
30242094Nano-delivery of <i>RAD6</i>/Translesion Synthesis Inhibitor SMI#9 for Triple-negative Breast Cancer Therapy.Mol Cancer Ther2018
30185422Strategy for Tumor-Selective Disruption of Androgen Receptor Function in the Spectrum of Prostate Cancer.Clin Cancer Res2018
30013182Krebs-cycle-deficient hereditary cancer syndromes are defined by defects in homologous-recombination DNA repair.Nat Genet2018
28928160Quantitative and Mechanistic Understanding of AZD1775 Penetration across Human Blood-Brain Barrier in Glioblastoma Patients Using an IVIVE-PBPK Modeling Approach.Clin Cancer Res2017
27318641An aqueous normal-phase chromatography coupled with tandem mass spectrometry method for determining unbound brain-to-plasma concentration ratio of AZD1775, a Wee1 kinase inhibitor, in patients with glioblastoma.J Chromatogr B Analyt Technol Biomed Life Sci2016
26563438Gold nanoparticle conjugated Rad6 inhibitor induces cell death in triple negative breast cancer cells by inducing mitochondrial dysfunction and PARP-1 hyperactivation: Synthesis and characterization.Nanomedicine2016
25955381A liquid chromatography with tandem mass spectrometry method for simultaneous determination of UTL-5g and its metabolites in human plasma.J Chromatogr B Analyt Technol Biomed Life Sci2015
26473433Evaluation of Hybrid Theoretical Approaches for Structural Determination of a Glycine-Linked Cisplatin Derivative via Infrared Multiple Photon Dissociation (IRMPD) Action Spectroscopy.J Phys Chem A2015
24413091Amino acid-linked platinum(II) analogues have altered specificity for RNA compared to cisplatin.Chem Commun (Camb)2014
  • 1 - 33 of 33

Recommended Authors

Priya Kumthekar
Northwestern University, Feinberg School of Medicine
Career Start Year 2013
Number of shared co-authors 2
Johannes C van der Mijn
New York Presbyterian Hospital
Career Start Year 2012
Number of shared co-authors 0
Marzia Del Re
University of Pisa
Career Start Year 2010
Number of shared co-authors 1
Donggeon Kim
Institute for Refractory Cancer Research, Samsung Medical Center
Career Start Year 2009
Number of shared co-authors 0
Rajendar K Mittapalli
Pfizer Inc.
Career Start Year 2008
Number of shared co-authors 0
Ahmed Aman
Ontario Institute for Cancer Research, University Avenue
Career Start Year 2007
Number of shared co-authors 1
John F Reilly
Goldfinch Bio Inc.
Career Start Year 2007
Number of shared co-authors 0
Jordi Rodon
The University of Texas MD Anderson Cancer Center
Career Start Year 2006
Number of shared co-authors 0
Kari M Morrissey
Amunix Pharmaceuticals
Career Start Year 2006
Number of shared co-authors 0
Paul Hamberg
Franciscus Gasthuis & Vlietland Hospital Rotterdam and Schiedam
Career Start Year 2006
Number of shared co-authors 2
Shubham Pant
The University of Texas MD Anderson Cancer Center
Career Start Year 2005
Number of shared co-authors 0
Shuiying Hu
The Ohio State University
Career Start Year 2005
Number of shared co-authors 1
Lie Li
Sino-French Hoffmann Institute, Guangzhou Medical University
Career Start Year 2003
Number of shared co-authors 1
Neeltje Steeghs
Netherlands Cancer Institute-Antoni Van Leeuwenhoek
Career Start Year 2003
Number of shared co-authors 2
Mar??a Jos?? Guill??n
Instituto de Investigaciones Biomedicas "Alberto Sols"
Career Start Year 2001
Number of shared co-authors 0
Cristina Rodr??guez-Antona
Spanish National Cancer Research Center (CNIO)
Career Start Year 2000
Number of shared co-authors 0
Martijn P Lolkema
Erasmus MC Cancer Institute
Career Start Year 1999
Number of shared co-authors 2
Salvador Fudio
Clinical Development
Career Start Year 1998
Number of shared co-authors 0
Christopher Calabrese
St. Jude Children's Research Hospital
Career Start Year 1997
Number of shared co-authors 0
Alice A Gibson
The Ohio State University
Career Start Year 1997
Number of shared co-authors 1
Sunil Sharma
Brody School of Medicine, East Carolina University
Career Start Year 1997
Number of shared co-authors 0
Lillian L Siu
Princess Margaret Cancer Centre, University Ave
Career Start Year 1995
Number of shared co-authors 0
Wells A Messersmith
University of Colorado Anschutz Medical Campus
Career Start Year 1995
Number of shared co-authors 1
Sharyn D Baker
Ohio State University
Career Start Year 1994
Number of shared co-authors 1
Jan H M Schellens
Department of Pharmaceutical Sciences, Utrecht University
Career Start Year 1987
Number of shared co-authors 1
Mark J Ratain
University of Chicago
Career Start Year 1985
Number of shared co-authors 0
Anne Monks
Institute of Biomedical Engineering (IBME), University of Oxford
Career Start Year 1976
Number of shared co-authors 0
James H Doroshow
National Cancer Institute, National Institutes of Health
Career Start Year 1974
Number of shared co-authors 1
Antonio Jimeno
University of Colorado School of Medicine
Career Start Year 1974
Number of shared co-authors 0
Paul Workman
The Institute of Cancer Research
Career Start Year 1974
Number of shared co-authors 1

Collaborators

Ranjit S Bindra
Yale University School of Medicine
Co-authored papers 5
Brian Shuch
University of California los angeles
Co-authored papers 4
Guan Wang
Jilin University
Co-authored papers 2
Jing Li
Karmanos Cancer Institute, Wayne State University
Co-authored papers 2
Shwetal Mehta
Barrow Neurological Institute, St. Joseph's Hospital and Medical Center
Co-authored papers 2
Ranjini K Sundaram
Yale University
Co-authored papers 2
Daiki Ueno
Institute of Urologic Oncology, University of California Los Angeles
Co-authored papers 2
An-Chi Tien
Barrow Neurological Institute, St. Joseph's Hospital & Medical Center
Co-authored papers 2
Joshua D Rabinowitz
Lewis Sigler Institute for Integrative Genomics, Princeton University
Co-authored papers 2
Randy Caliliw
David Geffen School of Medicine at university of california los angeles
Co-authored papers 1
Shinji Ohtake
Institute of Urologic Oncology, University of California los angeles
Co-authored papers 1
Alex Sparreboom
Ohio State University
Co-authored papers 1
Jinny van Doorn
Yale University School of Medicine
Co-authored papers 1
David Schiff
University of Virginia School of Medicine
Co-authored papers 1
Rong-Rong Huang
Stomatology Hospital, Zhejiang University School of Medicine
Co-authored papers 1
Roberto Fiorelli
Barrow Neurological Institute
Co-authored papers 1
Juan C Vasquez
Yale School of Medicine
Co-authored papers 1
Jiayu Liang
institute of urology
Co-authored papers 1
Amrita Sule
Yale University
Co-authored papers 1
Paul C Boutros
University of California los angeles
Co-authored papers 1
Karla Boyd
Yale University School of Medicine
Co-authored papers 1
Jack Dodson
University of California los angeles
Co-authored papers 1
Huihui Ye
College of Optical Science and Engineering, Zhejiang University
Co-authored papers 1
Sam Friedman
Yale University School of Medicine
Co-authored papers 1
Release 1.2